title: Radiation therapy and surgery for fibrosarcoma in 33 cats.
abstract: Thirty-three cats with histologically confirmed fibrosarcomas were treated with radiation therapy followed by surgery. The median (95% confidence interval) disease free interval and overall survival were 398 (261,924) and 600 (lower limit 515) days, respectively. There were 19 treatment failures; 11 cats had only local recurrence, 4 cats developed metastatic disease, 3 cats had local recurrence followed by metastasis, and 1 cat developed simultaneous local and distant disease. Twelve cats are alive and disease free. Two cats died without evidence of treatment failure. The presence of tumor cells at the margin of resected tissue after radiation was the only variable which influenced treatment success. The median (95% confidence interval) disease free interval in 5 cats with tumor cells at the margin of the resected specimen was 112 (94,150) days versus 700 (lower limit 328) days for 26 cats with negative tumor margins, p < 0.0001. We did not identify a relationship between tumor volume, number of prior tumor excisions, concomitant use of chemotherapy or various descriptors of the radiation therapy technique and disease free interval.
authors.affiliation: College of Veterinary Medicine, North Carolina State University, Raleigh 27606, USA.
authors.forename: K
authors.initials: K
authors.lastname: Cronin
authors.forename: R L
authors.initials: RL
authors.lastname: Page
authors.forename: G
authors.initials: G
authors.lastname: Spodnick
authors.forename: R
authors.initials: R
authors.lastname: Dodge
authors.forename: E N
authors.initials: EN
authors.lastname: Hardie
authors.forename: G S
authors.initials: GS
authors.lastname: Price
authors.forename: D
authors.initials: D
authors.lastname: Ruslander
authors.forename: D E
authors.initials: DE
authors.lastname: Thrall
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D002371:Cat Diseases / Q000532:radiotherapy* / Q000601:surgery; D002415:Cats; D017024:Chemotherapy, Adjuvant / Q000662:veterinary; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D016001:Confidence Intervals; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005354:Fibrosarcoma / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery / Q000662:veterinary*; D005500:Follow-Up Studies; D008175:Lung Neoplasms / Q000556:secondary / Q000662:veterinary; D008207:Lymphatic Metastasis; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000662:veterinary; D009367:Neoplasm Staging / Q000662:veterinary; D018365:Neoplasm, Residual / Q000662:veterinary; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011879:Radiotherapy Dosage / Q000662:veterinary; D012086:Reoperation / Q000662:veterinary; D012189:Retrospective Studies; D012983:Soft Tissue Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000662:veterinary*; D015996:Survival Rate; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D003037:Cobalt Radioisotopes; D019275:Radiopharmaceuticals; D004317:Doxorubicin